



PRESS RELEASE

## ***Notice of publication of the Annual Report 2019 and other documents for the Shareholders' meeting on April 27<sup>th</sup>, 2020.***

Milan (Italy), April 6<sup>th</sup> 2020 – MolMed S.p.A. (MLMD.MI) (the “Company”), a biotechnology company focused on research, development, production and clinical validation of gene and cell therapies for the treatment of cancer and rare diseases, informs that the following documents are available to the public at the Company’s registered office, on the Company’s website ([www.molmed.com](http://www.molmed.com)) in the sections Investor Relations/Shareholders’ Meeting, and in the authorized storage system 1Info ([www.1info.it](http://www.1info.it)):

- Annual Financial Report 2019, including draft Financial Statements of MolMed as at December, 31<sup>st</sup> 2019, together with the Report on Operations and prescribed certifications, the Independent auditors’ Report and the Statutory auditors’ Report (pursuant to article 154-*ter*, paragraph 1 of the Legislative Decree 58/98)
- Annual Report on Corporate Governance and Ownership Structure (pursuant to article 123-*bis* of Legislative Decree 58/98).
- Annual Report on Remuneration (pursuant to article 123-*ter* of Legislative Decree 58/98).

### ***About MolMed***

MolMed S.p.A. is a clinical stage biotech company focused on research, development, manufacturing and clinical validation of innovative therapies. MolMed is the first company in Europe to have obtained the GMP manufacturing authorization for cell & gene therapies *ex vivo* for its proprietary products as well as for third parties and/or in partnership (Strimvelis, an Orchard gene therapy for the ADA-SCID). With reference to GMP development and manufacturing activities for third parties, MolMed signed numerous partnership agreements with leading European and US companies. MolMed’s is also developing a new therapeutic platform based on Chimeric Antigen Receptor (CAR), both autologous and allogeneic; the most advanced product, CAR-T CD44v6, which in March 2019 received the authorization to start human clinical trials in onco-hematologic indications (AML and MM), following an extensive pre-clinical phase. MolMed, founded in 1996 as an academic spin-off of the San Raffaele Scientific Institute, is listed on the main market (MTA) of the Milan stock exchange managed by Borsa Italiana since March 2008. MolMed is headquartered and based in Milan, at the San Raffaele Biotechnology Department (DIBIT) and has an operating unit at OpenZone in Bresso. For more information please visit [www.molmed.com](http://www.molmed.com).

### ***For further information:***

**Ilaria Candotti**  
*Investor Relations & Communication Manager*  
MolMed S.p.A.  
+39 02 21277.205  
[investor.relations@molmed.com](mailto:investor.relations@molmed.com)

**Tommasina Cazzato**  
*Press Office*  
Community Group  
+39 345 7357751  
[tommasina.cazzato@communitygroup.it](mailto:tommasina.cazzato@communitygroup.it)